Advertisement
UK markets closed

  • FTSE 100

    7,895.85
    +18.80 (+0.24%)
     

  • FTSE 250

    19,391.30
    -59.37 (-0.31%)
     

  • AIM

    745.67
    +0.38 (+0.05%)
     

  • GBP/EUR

    1.1607
    -0.0076 (-0.65%)
     

  • GBP/USD

    1.2370
    -0.0068 (-0.55%)
     

  • Bitcoin GBP

    52,059.04
    +707.88 (+1.38%)
     

  • CMC Crypto 200

    1,334.09
    +21.46 (+1.64%)
     

  • S&P 500

    4,967.23
    -43.89 (-0.88%)
     

  • DOW

    37,986.40
    +211.02 (+0.56%)
     

  • CRUDE OIL

    83.24
    +0.51 (+0.62%)
     

  • GOLD FUTURES

    2,406.70
    +8.70 (+0.36%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • HANG SENG

    16,224.14
    -161.73 (-0.99%)
     

  • DAX

    17,737.36
    -100.04 (-0.56%)
     

  • CAC 40

    8,022.41
    -0.85 (-0.01%)
     
Property:

11 beautiful homes with glorious garden rooms

Investing in a home with a garden room will enable you to enjoy your outside space whatever the weather

Retinal Vein Occlusion - Competitive Landscape in 2021

ReportLinker
·2-min read

Summary In RVO, Vascular Endothelial Growth Facto (VEGF) is a major focus of drug developers. There are 24 drugs in the pipeline with 80% molecules present in early stage.

New York, April 14, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Retinal Vein Occlusion - Competitive Landscape in 2021" - https://www.reportlinker.com/p06058321/?utm_source=GNW


Mid-sized Pharma dominates R&D in this indication. The increasing prevalence and preference for branded therapies will drive the market’s growth over the next six years, but the high cost of branded therapies is expected to limit their uptake.

This reports provides a data-driven overview of the current and future competitive landscape in Retinal Vein Occlusion (RVO) therapeutics.

Retinal Vein Occlusion (RVO) - Competitive Landscape in 2021 combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Scope
Components of the report include -
- Disease epidemiology
- Marketed drugs assessment
- Pipeline drugs assessment
- Clinical trials assessment
- Commercial assessment
- Social media overview
- Digital marketing overview

The accompanying Excel file includes the following datasets -
- Marketed products exported from Pharmaceutical Intelligence Center
- Pipeline-stage products exported from Pharmaceutical Intelligence Center
- Upcoming catalysts in the RVO market exported from the Catalyst Calendar on Pharmaceutical Intelligence Center
- A list of patent expiry dates for RVO products

Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global RVO market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global RVO market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Read the full report: https://www.reportlinker.com/p06058321/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001